Recruiting Esophageal Cancer Studies in New York
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
This is a Phase 1/2, multicenter, randomized, open-label umbrella platform study to evaluate the safety and efficacy of investigational agents with or without pembrolizumab and/or chemotherapy, for th...
Substudy 06C: A Study of Sacituzumab Tirumotecan (MK-2870) With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
This is a phase 1/2, multicenter, open-label umbrella platform study that will evaluate the safety and tolerability of sacituzumab tirumotecan with pembrolizumab and fluoropyrimidine chemotherapy for ...
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
This is a phase 1/2 multicenter, open-label umbrella platform study that will evaluate the safety and efficacy of sacituzumab tirumotecan (MK-2870) plus paclitaxel versus ramucirumab plus paclitaxel, ...
A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer
The purpose of this study to find out whether adding trastuzumab and pembrolizumab to standard chemotherapy is an effective treatment for resectable HER2+ esophagogastric cancer....
Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction
An open label phase II study to determine the safety and preliminary efficacy of the combination of 1-year of adjuvant trastuzumab deruxtecan and nivolumab for patients with HER2 overexpressing esopha...
About Esophageal Cancer Clinical Trials in New York
Esophageal cancer occurs in the esophagus, the tube connecting the throat to the stomach. The two main types are squamous cell carcinoma and adenocarcinoma. Treatment may include surgery, chemotherapy, radiation, and immunotherapy.
There are currently 5 esophageal cancer clinical trials recruiting participants in New York, NY. These studies are seeking a combined 524 participants. Research is being sponsored by Merck Sharp & Dohme LLC, Memorial Sloan Kettering Cancer Center, Brown University. Clinical trial participation is free and participants receive study-related medical care at no cost.
Esophageal Cancer Clinical Trials in New York — FAQ
Are there esophageal cancer clinical trials in New York?
Yes, there are 5 esophageal cancer clinical trials currently recruiting in New York, NY. Browse the studies on this page to find one that fits.
How do I join a clinical trial in New York?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the New York research site will contact you about next steps.
Are clinical trials in New York free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many New York studies also compensate for your time and travel.
What esophageal cancer treatments are being tested?
The 5 active trials in New York are testing new therapies including novel drugs, biologics, and treatment approaches for esophageal cancer.
Data updated March 2, 2026 from ClinicalTrials.gov